Want to join the conversation?
Global pharmaceutical company $AGN said new data on investigational medication rapastinel (GLYX-13) and its lack of impairment on cognitive function were published in peer-reviewed journal Behavioural Brain Research. The goal of this study was to compare effects on cognition of rapastinel and ketamine in novel object recognition (NOR) in mice.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.